Nanobiotix (NASDAQ:NBTX) Shares Gap Down - Time to Sell?

Key Points

• Nanobiotix's share price gapped down from $22.18 to $20.20 before the market opened on Thursday, with a trading volume of 61,836 shares.
• Analysts have mixed ratings on Nanobiotix, with two analysts giving a "buy" rating, one a "hold," and one a "sell," resulting in a consensus rating of "hold" and an average target price of $11.00.
• Nanobiotix focuses on developing products for cancer treatment, with its leading candidate being NBTXR3, which uses hafnium oxide nanoparticles for various cancer types.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $22.18, but opened at $20.20. Nanobiotix shares last traded at $20.20, with a volume of 61,836 shares traded.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NBTX shares. HC Wainwright reissued a "buy" rating on shares of Nanobiotix in a research report on Friday, September 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Nanobiotix in a research report on Wednesday, October 8th. Finally, Leerink Partners set a $14.00 price objective on Nanobiotix in a research report on Thursday, September 18th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $11.00.

Nanobiotix Price Performance

The firm has a 50-day moving average of $15.09 and a 200 day moving average of $8.22.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.